

R&D PORTFOLIO June 2024 – 13 treatments delivered

| | DISCOVERY | | | TRANSLATION | | | DEVELOPMENT | | IMPLEMENTATION | |
|------------------------------------|----------------------------|-------------|-----------------------|--------------------------|--------------------------------|----------------------------------|--------------------------------------|--|---|------------------------------------|
| | Screen | Hit-to-lead | Lead optimization | Pre-clinical | Phase I | Phase IIa/ Proof-of-concept | Phase IIb/III | Registration | Treatment access | |
| Sleeping sickness | | | | | | | Acoziborole + | | Fexinidazole for <i>T.b. gambiense</i> * + Fexinidazole for <i>Tb. rhodesiense</i> * + Nifurtimox-eflornithine combination therapy (NECT)* | |
| Leishmaniasis | Screening | | | DNDI-6174 + | DNDI-6148 + | LXE408 Novartis for VL + | Miltefosine + thermo-therapy for CL | Miltefosine + paromomycin for VL (Africa) | SSG + PM (East Africa)* | |
| | | | | DNDI-8526 (S07 series) + | DNDI-0690 + | | LAmB +/- miltefosine for PKDL (Asia) | Miltefosine + paromomycin or LAmB for PKDL (Sudan) | New VL treatments (South Asia)* | |
| | | | | | DNDI-6899 (GSK899 DDD853651) + | | | | | New treatments for VL/HIV* |
| | | | | | CpG-D35 (DNDI-2319) + | | | | | New VL treatments (Latin America)* |
| | | | GSK245 (DDD1305143) + | | | | | | | |
| Chagas disease | Screening | Hit-to-lead | UW series + | Biomarkers | DNDI-6148 + | | | | | |
| | | | MT series + | | | | New benznidazole regimens | | Benznidazole paediatric dosage forms* | |
| Filaria: River blindness | | | | DNDI-6166 (CC6166) + | | Emodepside + Oxfendazole + | | | | |
| Mycetoma | | | | | | | | Fosravuconazole | New treatments for mycetoma | |
| Dengue | | | | Pre-clinical profiling | | | | | | |
| HIV | | | | | | SR 5FC (cryptococcal meningitis) | | | Super-booster for children with HIV/TB* 4-in-1 (ABC/3TC/LPV/r)* and other DAAs AHD access (incl. 5FC, LAmB for cryptococcal meningitis) 2-in-1 LPV/r pellets | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| Hepatitis C | | | | | | | | | Ravidasvir* and other DAAs + | |
| COVID-19/ Pandemic preparedness | Nucleo- side Booster | | TMEM16 series + | | | | | ANTICOV | | |
| | | | AVIDD ASAP + | | | | | | | |
| Malaria » | | | | | | | | | Fixed-dose combination ASMQ* Fixed-dose combination ASAQ* | |
| | | | | | | | | | | |

» Implementation transferred to the Medicines for Malaria Venture in 2015

+ New chemical entity (NCE) or NCE-enabling project

* Treatments delivered by DNDi with partners

» Treatments not delivered by DNDi, but DNDi working on access